Shore Capital reiterated their buy rating on shares of Cohort (LON:CHRT – Free Report) in a research note published on Tuesday morning, Marketbeat reports.
Cohort Trading Up 1.4 %
Shares of CHRT stock opened at GBX 844 ($11.30) on Tuesday. The business has a 50-day moving average of GBX 844.50 and a 200 day moving average of GBX 785.44. The company has a debt-to-equity ratio of 36.88, a current ratio of 1.55 and a quick ratio of 0.93. Cohort has a 1-year low of GBX 456 ($6.11) and a 1-year high of GBX 900 ($12.05). The stock has a market capitalization of £341.23 million, a PE ratio of 2,221.05 and a beta of 0.56.
Cohort Increases Dividend
The company also recently announced a dividend, which will be paid on Wednesday, October 2nd. Stockholders of record on Thursday, August 22nd will be issued a GBX 10.10 ($0.14) dividend. This is a boost from Cohort’s previous dividend of $4.70. The ex-dividend date is Thursday, August 22nd. This represents a dividend yield of 1.22%. Cohort’s dividend payout ratio (DPR) is currently 3,947.37%.
Insider Activity at Cohort
Cohort Company Profile
Cohort plc, through its subsidiaries, provides various products and services in defense, security, and related markets in the United Kingdom, Germany, Portugal, Africa, North and South America, and the Asia Pacific and Africa. The company offers electro-optical and electro-mechanical systems, such as command, control, communications, computers, intelligence, surveillance, target acquisition, and reconnaissance, as well as combat systems; and communications systems.
Further Reading
- Five stocks we like better than Cohort
- Roth IRA Calculator: Calculate Your Potential Returns
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- What Are Growth Stocks and Investing in Them
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Cohort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cohort and related companies with MarketBeat.com's FREE daily email newsletter.